Cybin Inc. (OTCMKTS:CYBN – Get Free Report) shares were down 5.3% on Thursday . The stock traded as low as $0.40 and last traded at $0.41. Approximately 5,637,068 shares were traded during mid-day trading, an increase of 5% from the average daily volume of 5,370,952 shares. The stock had previously closed at $0.43.
Cybin Trading Down 5.3 %
The firm has a market capitalization of $167.30 million, a PE ratio of -1.94 and a beta of 0.38. The firm has a 50-day moving average of $0.37 and a two-hundred day moving average of $0.43.
Cybin (OTCMKTS:CYBN – Get Free Report) last issued its earnings results on Wednesday, February 14th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.04). Equities research analysts expect that Cybin Inc. will post -0.19 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Cybin Company Profile
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
Further Reading
- Five stocks we like better than Cybin
- How to Capture the Benefits of Dividend Increases
- 3 Value Stocks Too Small For Buffett’s Portfolio
- Bank Stocks – Best Bank Stocks to Invest In
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- How to Use the MarketBeat Stock Split Calculator
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.